Author

Heather Wightman

Observed names: H Wightman, Wightman H, Wightman, Heather

Observed institutions: Dalhousie University, Amsterdam Public Health, Torrens University Australia, Stockholm Gerontology Research Center Foundation, University of Glasgow, Amsterdam UMC Location Vrije Universiteit Amsterdam

ORCID: 0009-0009-3625-0945

Observed ORCID: 0009-0009-3625-0945

OpenAlex ID: A5068422864

The relationship between frailty and social vulnerability: a systematic review

2024 · Peter Hanlon, Heather Wightman, et al. · The Lancet Healthy Longevity · 144

Frailty and socioeconomic position: A systematic review of observational studies

2024 · Peter Hanlon, Marina Politis, et al. · Ageing Research Reviews · 77

Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes

2025 · Peter Hanlon, Elaine Butterly, et al. · JAMA · 45

Frailty in randomized controlled trials of glucose-lowering therapies for type 2 diabetes: An individual participant data meta-analysis of frailty prevalence, treatment efficacy, and adverse events

2025 · Heather Wightman, Elaine Butterly, et al. · PLoS Medicine · 17

Frailty in randomised controlled trials for dementia or mild cognitive impairment measured via the frailty index: prevalence and prediction of serious adverse events and attrition

2023 · Heather Wightman, Terry J. Quinn, et al. · Alzheimer s Research & Therapy · 14

PDF

Does the frailty index applied to randomised controlled trials really measure frailty?

2025 · Rîme Bousetta, David A McAllister, et al. · Age and Ageing · 8

Assessing the representativeness of trials of Sodium-glucose Cotransporter-2 inhibitors in type 2 diabetes: a comparison of individual-level trial data and people newly prescribed treatment in a Welsh routine care database

2025 · Peter Hanlon, Heather Wightman, et al. · BMC Medicine · 2

PDF

Age- and sex- differences in efficacy of treatments for type 2 diabetes: Network meta-analysis of aggregate and individual level data

2024 · Peter Hanlon, Elaine Butterly, et al. · medRxiv · 2

Comparing age, comorbidity and event rates between SGLT2 inhibitor trial participants and people treated in routine care

2026 · P Hanlon, H Wightman, et al. · Live Repository

Frailty in randomised controlled trials for dementia or mild cognitive impairment

2026 · Heather Wightman, Terry Quinn, et al. · Live Repository

3818 Comparing age, comorbidity and event rates between SGLT2 inhibitor trial participants and people treated in routine care

2026 · P Hanlon, H Wightman, et al. · Age and Ageing

3820 Does the frailty index applied to randomised controlled trials really measure frailty?

2026 · R Bousetta, D A McAllister, et al. · Age and Ageing

2834 Frailty in randomised controlled trials of glucose-lowering therapies for type 2 diabetes

2025 · H Wightman, E Butterly, et al. · Age and Ageing

2836 Age differences in efficacy of newer glucose lowering treatments for type 2 diabetes

2025 · P Hanlon, E Butterly, et al. · Age and Ageing

Frailty in Randomised Controlled Trials of Glucose-Lowering Therapies for Type 2 Diabetes: An Individual Participant Data Meta-Analysis of Frailty Prevalence, Treatment Efficacy, and Adverse Events

2024 · Heather Wightman, Elaine Butterly, et al. · SSRN Electronic Journal

1311 Frailty in Randomised Controlled Trials for Dementia or Mild Cognitive Impairment

2023 · H Wightman, T Quinn, et al. · Age and Ageing

PDF

Assessing Frailty in Clinical Trials for Dementia or Cognitive Impairment

2023 · Peter Hanlon, Heather Wightman, et al.

PDF

Frailty in randomized controlled trials of glucose-lowering therapies for type 2 diabetes: An individual participant data meta-analysis of frailty prevalence, treatment efficacy, and adverse events

· Wightman H, Butterly E, et al. · Newcastle University ePrints (Newcastle Univesity)

PDF

Works count: 21

Citation count: 309

H-index: 6

I10-index: 5